(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070270 A1

(51) **International Patent Classification**[7]: **A61K 39/00**, A61P 31/18

(21) **International Application Number:** PCT/AU03/00207

(22) **International Filing Date:** 18 February 2003 (18.02.2003)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
PS 0650 20 February 2002 (20.02.2002) AU

(71) **Applicant** *(for all designated States except US)*: **IMMUNAID PTY LTD** [AU/AU]; 60-66 Hanover Street, Fitzroy, Victoria 3065 (AU).

(72) **Inventor; and**
(75) **Inventor/Applicant** *(for US only)*: **ASHDOWN, Martin, Leonard** [AU/AU]; 140 Keon Street, Thornbury, Victoria 3071 (AU).

(74) **Agent: F B RICE & CO**; 139 Rathdowne Street, Carlton, Victoria 3053 (AU).

(81) **Designated States** *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/070270 A1

(54) **Title:** STRATEGY FOR RETROVIRAL IMMUNOTHERAPY

(57) **Abstract:** The present inventor has noted that at least two populations of immune cells are produced in response to retroviruses which infect mammals. More particularly, the immune system of a mammal infected with a retrovirus is capable of mounting an immune response against the virus through a group of cells herein generally referred to as "effector cells", however, a second population of cells are also produced which regulate the "effector cells", herein generally referred to as "regulator cells" (or suppressor cells), limiting the mammal's ability to effectively control or eradicate the retroviral infection. Accordingly, the present invention utilizes these observations to provide methods for treating a mammal with a retroviral infection. Furthermore, the present inventor has found that acute phase inflammatory markers can be used to detect and monitor an"effector cell" response to retroviral antigens.